A Promise Without Panacea: Psychedelic-Assisted Therapies in Modern Psychiatry.
Cureus January 1, 2026 Mohsin Raza, Jasleen Kaur
Psychedelic-assisted therapies are gaining renewed scientific and clinical interest in psychiatry, especially for treatment-resistant depression, post-traumatic stress disorder, and substance use disorders. Compounds like psilocybin and MDMA show promising therapeutic effects in controlled clinical trials when used within structured psychotherapeutic frameworks. Neurobiological evidence suggests these agents may promote neural plasticity and enhance cognitive and emotional flexibility, potentially leading to durable clinical improvement. However, significant challenges remain, including regulatory uncertainty, methodological limitations in trials, ethical concerns about patient vulnerability, and equitable access. The editorial highlights both the therapeutic potential and critical considerations for responsible integration into mental health care.